Viridian Therapeutics has announced positive Phase 1 results for VRDN-008, an investigational subcutaneous therapy designed to treat autoantibody-mediated autoimmune diseases, reporting sustained immunoglobulin G (IgG) reductions that could support dosing every eight weeks.
According to the company's November 2026 announcement, VRDN-008 achieved a peak IgG reduction of 74% in healthy volunteers, with suppression maintained for up to eight weeks following administration. The findings suggest the therapy could provide longer-lasting disease control with fewer injections than existing treatment approaches.
Although Viridian's immediate clinical focus remains thyroid eye disease (TED), the company is also expanding its pipeline into other autoimmune conditions, beginning with myasthenia gravis (MG).
VRDN-008 is a half-life-extended neonatal Fc receptor (FcRn) inhibitor designed to reduce circulating IgG antibodies, including those implicated in autoimmune diseases. The Phase 1 study evaluated subcutaneous administration in healthy volunteers, who received two doses of VRDN-008: one at baseline and another at week four. The results demonstrated an extended drug half-life of 15–18 days, approximately six times longer than first-generation Fc fragments. This prolonged activity could potentially enable less frequent treatment while maintaining sustained IgG suppression. The investigational therapy was also generally well tolerated, with no serious adverse events or dose-limiting toxicities reported. Importantly, treatment did not produce reductions in albumin or low-density lipoprotein (LDL) cholesterol.
“Today’s VRDN-008 data exceeded expectations and demonstrates a potentially transformative FcRn-inhibitor profile,” said Steve Mahoney, president and CEO of Viridian Therapeutics.
Following the positive results, Viridian plans to initiate at least one pivotal clinical trial in 2027, beginning with MG in mid-2027, subject to regulatory feedback. The proposed placebo-controlled study will evaluate dosing every four and eight weeks, potentially supporting a direct pathway toward registration. Viridian also intends to investigate VRDN-008 across additional autoantibody-mediated diseases, although specific indications beyond MG have not yet been confirmed.
While the news is not directly applicable to ophthalmologists, the announcement represents a development worth monitoring given Viridian's established involvement in TED therapeutics and the autoimmune mechanisms underlying the condition. However, VRDN-008 has not yet demonstrated clinical benefit in TED, and the company has not announced a TED-specific development program for the drug. Further clinical trials will therefore be needed to determine whether its prolonged IgG suppression translates into meaningful patient outcomes.
Source:Viridian Therapeutics.